NCT06025773View on ClinicalTrials.gov

A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 15, 2023

Primary Completion Date

April 19, 2024

Study Completion Date

April 19, 2024

Conditions
Gastro Esophageal Reflux
Interventions
DRUG

Lansoprazole 15 mg

AD-2121 (Lansoprazole 15 mg), Oral, Capsule

DRUG

Lansoprazole 15mg/Calcium carbonate 600mg

AD-212-A (Lansoprazole 15mg/Calcium carbonate 600mg), Oral, Tablet

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Addpharma Inc.

INDUSTRY

NCT06025773 - A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-212-A and AD-2121 | Biotech Hunter | Biotech Hunter